• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tregs 仿生纳米颗粒可重编程梗死组织中的炎症和氧化还原微环境，从而治疗小鼠心肌缺血再灌注损伤。

Tregs biomimetic nanoparticle to reprogram inflammatory and redox microenvironment in infarct tissue to treat myocardial ischemia reperfusion injury in mice.

机构信息

Department of Pharmaceutics, School of Pharmacy, Air Force Medical University, Changle West Road 169, Xi'an, 710032, Shaanxi, China.

Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Department of Pharmacology, School of Pharmacy, Air Force Medical University, Xi'an, 710032, China.

出版信息

J Nanobiotechnology. 2022 Jun 3;20(1):251. doi: 10.1186/s12951-022-01445-2.

DOI:10.1186/s12951-022-01445-2
PMID:35659239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9164893/
Abstract

BACKGROUND

At present, patients with myocardial infarction remain an increased risk for myocardial ischemia/reperfusion injury (MI/RI). There lacks effectively method to treat MI/RI in clinic. For the treatment of MI/RI, it is still a bottleneck to effectively deliver drug to ischemic myocardium. In this paper, a regulatory T cells (Tregs) biomimetic nanoparticle (CsA@PPTK) was prepared by camouflaging nanoparticle with platelet membrane.

RESULTS

CsA@PPTK actively accumulated in ischemic myocardium of MI/RI mice. CsA@PPTK significantly scavenged reactive oxygen species (ROS) and increased the generation of Tregs and the ratio of M2 type macrophage to M1 type macrophage in ischemic myocardium. Moreover, CsA@PPTK significantly attenuated apoptosis of cardiomyocytes and reduced the infarct size and fibrosis area in ischemic myocardium. CsA@PPTK markedly decreased the protein expression of MMP-9 and increased the protein expression of CX43 in ischemic myocardium tissue. Subsequently, the remodeling of the left ventricle was significant alleviated, and heart function of MI/RI mice was markedly improved.

CONCLUSION

CsA@PPTK showed significant therapeutic effect on MI/RI, and it has great potential application in the treatment of MI/RI.

摘要

背景

目前，心肌梗死患者仍然存在心肌缺血/再灌注损伤（MI/RI）的风险增加。临床上缺乏有效的治疗 MI/RI 的方法。对于 MI/RI 的治疗，将药物有效递送到缺血心肌仍然是一个瓶颈。在本文中，通过将纳米颗粒伪装成血小板膜，制备了调节性 T 细胞（Tregs）仿生纳米颗粒（CsA@PPTK）。

结果

CsA@PPTK 在 MI/RI 小鼠的缺血心肌中主动积聚。CsA@PPTK 可显著清除活性氧（ROS），增加缺血心肌中 Tregs 的产生和 M2 型巨噬细胞与 M1 型巨噬细胞的比例。此外，CsA@PPTK 可显著减轻心肌细胞凋亡，减少缺血心肌中的梗死面积和纤维化面积。CsA@PPTK 明显降低了缺血心肌组织中 MMP-9 的蛋白表达，增加了 CX43 的蛋白表达。随后，左心室重构明显缓解，MI/RI 小鼠的心功能明显改善。

结论

CsA@PPTK 对 MI/RI 具有显著的治疗作用，在 MI/RI 的治疗中具有很大的应用潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/3a4a93a1ab84/12951_2022_1445_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/0915669464d1/12951_2022_1445_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/aab49251fc88/12951_2022_1445_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/ba2f716cabf5/12951_2022_1445_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/e60c4ea698e7/12951_2022_1445_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/967c2872282b/12951_2022_1445_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/5cd9e015909f/12951_2022_1445_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/8dfaf3d19261/12951_2022_1445_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/1bf19ccf8083/12951_2022_1445_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/3a4a93a1ab84/12951_2022_1445_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/0915669464d1/12951_2022_1445_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/aab49251fc88/12951_2022_1445_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/ba2f716cabf5/12951_2022_1445_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/e60c4ea698e7/12951_2022_1445_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/967c2872282b/12951_2022_1445_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/5cd9e015909f/12951_2022_1445_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/8dfaf3d19261/12951_2022_1445_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/1bf19ccf8083/12951_2022_1445_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b32/9164893/3a4a93a1ab84/12951_2022_1445_Fig8_HTML.jpg

相似文献

1
Tregs biomimetic nanoparticle to reprogram inflammatory and redox microenvironment in infarct tissue to treat myocardial ischemia reperfusion injury in mice.Tregs 仿生纳米颗粒可重编程梗死组织中的炎症和氧化还原微环境，从而治疗小鼠心肌缺血再灌注损伤。
J Nanobiotechnology. 2022 Jun 3;20(1):251. doi: 10.1186/s12951-022-01445-2.
2
Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats.线粒体靶向环孢素 A 递药系统治疗大鼠心肌缺血再灌注损伤。
J Nanobiotechnology. 2019 Jan 25;17(1):18. doi: 10.1186/s12951-019-0451-9.
3
Cyclosporine A-loaded apoferritin alleviates myocardial ischemia-reperfusion injury by simultaneously blocking ferroptosis and apoptosis of cardiomyocytes.载环孢素 A 的去铁铁蛋白通过同时阻断心肌细胞的铁死亡和细胞凋亡来减轻心肌缺血再灌注损伤。
Acta Biomater. 2023 Apr 1;160:265-280. doi: 10.1016/j.actbio.2023.02.025. Epub 2023 Feb 21.
4
Engineered Biomimetic Nanoplatform Protects the Myocardium Against Ischemia/Reperfusion Injury by Inhibiting Pyroptosis.工程仿生纳米平台通过抑制细胞焦亡来保护心肌免受缺血/再灌注损伤。
ACS Appl Mater Interfaces. 2021 Jul 28;13(29):33756-33766. doi: 10.1021/acsami.1c03421. Epub 2021 Jul 14.
5
Cyclosporine A loaded brain targeting nanoparticle to treat cerebral ischemia/reperfusion injury in mice.载环孢素 A 的脑靶向纳米粒治疗小鼠脑缺血/再灌注损伤。
J Nanobiotechnology. 2022 Jun 3;20(1):256. doi: 10.1186/s12951-022-01474-x.
6
Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury.艾塞那肽纳米颗粒复合物抗心肌缺血再灌注损伤的药理特征
Kidney Blood Press Res. 2018;43(4):1273-1284. doi: 10.1159/000492409. Epub 2018 Aug 3.
7
Inhibition of microRNA-327 ameliorates ischemia/reperfusion injury-induced cardiomyocytes apoptosis through targeting apoptosis repressor with caspase recruitment domain.抑制 microRNA-327 通过靶向含有半胱氨酸天冬氨酸酶募集结构域的凋亡抑制蛋白减轻缺血/再灌注损伤诱导的心肌细胞凋亡。
J Cell Physiol. 2020 Apr;235(4):3753-3767. doi: 10.1002/jcp.29270. Epub 2019 Oct 6.
8
A Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection From Myocardial Infarction.一种独特的调节性 T 细胞群体在心梗中增强心脏保护作用。
Circulation. 2020 Nov 17;142(20):1956-1973. doi: 10.1161/CIRCULATIONAHA.120.046789. Epub 2020 Sep 28.
9
Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion.鞘氨醇-1-磷酸受体激动剂 fingolimod 增加缺血/再灌注猪模型的心肌挽救并减少不良的梗死后左心室重构。
Circulation. 2016 Mar 8;133(10):954-66. doi: 10.1161/CIRCULATIONAHA.115.012427. Epub 2016 Jan 29.
10
Inhibited HDAC3 or Elevated MicroRNA-494-3p Plays a Protective Role in Myocardial Ischemia-Reperfusion Injury via Suppression of BRD4.抑制 HDAC3 或上调 microRNA-494-3p 通过抑制 BRD4 在心肌缺血再灌注损伤中发挥保护作用。
Mol Neurobiol. 2021 Sep;58(9):4268-4279. doi: 10.1007/s12035-021-02369-y. Epub 2021 May 12.

引用本文的文献

1
Advancements in nanomedicine for modulating ischemic cardiomyopathy therapy.用于调节缺血性心肌病治疗的纳米医学进展。
Mater Today Bio. 2025 Aug 23;34:102238. doi: 10.1016/j.mtbio.2025.102238. eCollection 2025 Oct.
2
Macrophage Polarization in Myocardial Ischemia‒Reperfusion Injury: Pathophysiology and Therapeutic Targets.心肌缺血-再灌注损伤中的巨噬细胞极化：病理生理学与治疗靶点
Drug Des Devel Ther. 2025 Jul 31;19:6519-6541. doi: 10.2147/DDDT.S516001. eCollection 2025.
3
Low Fluoride Regulates Macrophage Polarization Through Mitochondrial Autophagy Mediated by PINK1/Parkin Axis.

本文引用的文献

1
Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme.趋化因子驱动的和小胶质细胞仿生纳米颗粒治疗替莫唑胺耐药多形性胶质母细胞瘤。
J Control Release. 2021 Aug 10;336:54-70. doi: 10.1016/j.jconrel.2021.06.015. Epub 2021 Jun 12.
2
Immune Cells and Immunotherapy for Cardiac Injury and Repair.免疫细胞与免疫疗法在心脏损伤与修复中的作用。
Circ Res. 2021 May 28;128(11):1766-1779. doi: 10.1161/CIRCRESAHA.121.318005. Epub 2021 May 27.
3
The sooner, the better: anti-inflammation in acute myocardial infarction.
低氟通过PINK1/Parkin轴介导的线粒体自噬调节巨噬细胞极化
Biomolecules. 2025 Apr 30;15(5):647. doi: 10.3390/biom15050647.
4
Regulatory T cells: a promising new therapeutic target in ventricular remodeling after myocardial infarction.调节性T细胞：心肌梗死后心室重构中一个有前景的新治疗靶点。
Front Immunol. 2025 Apr 7;16:1514335. doi: 10.3389/fimmu.2025.1514335. eCollection 2025.
5
Injectable hydrogel with miR-222-engineered extracellular vesicles ameliorates myocardial ischemic reperfusion injury via mechanotransduction.含有经miR-222工程改造的细胞外囊泡的可注射水凝胶通过机械转导减轻心肌缺血再灌注损伤。
Cell Rep Med. 2025 Mar 18;6(3):101987. doi: 10.1016/j.xcrm.2025.101987. Epub 2025 Mar 3.
6
Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment.用于心肌梗死治疗的炎症细胞靶向递送系统
Bioengineering (Basel). 2025 Feb 19;12(2):205. doi: 10.3390/bioengineering12020205.
7
Nanomaterials: Promising Tools for the Diagnosis and Treatment of Myocardial Infarction.纳米材料：用于心肌梗死诊断和治疗的有前景的工具。
Int J Nanomedicine. 2025 Feb 11;20:1747-1768. doi: 10.2147/IJN.S500146. eCollection 2025.
8
Cardiac-targeted and ROS-responsive liposomes containing puerarin for attenuating myocardial ischemia-reperfusion injury.载葛根素的心脏靶向和 ROS 响应脂质体减轻心肌缺血再灌注损伤。
Nanomedicine (Lond). 2024;19(28):2335-2355. doi: 10.1080/17435889.2024.2402678. Epub 2024 Sep 24.
9
Reactive oxygen species (ROS)-responsive biomaterials for treating myocardial ischemia-reperfusion injury.用于治疗心肌缺血再灌注损伤的活性氧（ROS）响应性生物材料。
Front Bioeng Biotechnol. 2024 Sep 2;12:1469393. doi: 10.3389/fbioe.2024.1469393. eCollection 2024.
10
Nanomedicines as Guardians of the Heart: Unleashing the Power of Antioxidants to Alleviate Myocardial Ischemic Injury.纳米药物：守护心脏的卫士——利用抗氧化剂缓解心肌缺血性损伤
Theranostics. 2024 Aug 26;14(13):5336-5370. doi: 10.7150/thno.99961. eCollection 2024.
越快越好：急性心肌梗死中的抗炎作用
Eur Heart J. 2020 Nov 7;41(42):4100-4102. doi: 10.1093/eurheartj/ehaa752.
4
A Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection From Myocardial Infarction.一种独特的调节性 T 细胞群体在心梗中增强心脏保护作用。
Circulation. 2020 Nov 17;142(20):1956-1973. doi: 10.1161/CIRCULATIONAHA.120.046789. Epub 2020 Sep 28.
5
Platelet-Inspired Nanocells for Targeted Heart Repair After Ischemia/Reperfusion Injury.受血小板启发的纳米细胞用于缺血/再灌注损伤后的靶向心脏修复
Adv Funct Mater. 2019 Jan 24;29(4). doi: 10.1002/adfm.201803567. Epub 2018 Nov 13.
6
Platelets and their biomimetics for regenerative medicine and cancer therapies.血小板及其仿生材料在再生医学和癌症治疗中的应用。
J Mater Chem B. 2018 Dec 7;6(45):7354-7365. doi: 10.1039/C8TB02301H. Epub 2018 Oct 22.
7
Platelet Contributions to Myocardial Ischemia/Reperfusion Injury.血小板在心肌缺血/再灌注损伤中的作用。
Front Immunol. 2019 Jun 6;10:1260. doi: 10.3389/fimmu.2019.01260. eCollection 2019.
8
Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy.多前药纳米反应器诱导的线粒体特异性药物释放和活性氧爆发可以增强化疗。
Nat Commun. 2019 Apr 12;10(1):1704. doi: 10.1038/s41467-019-09566-3.
9
Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats.线粒体靶向环孢素 A 递药系统治疗大鼠心肌缺血再灌注损伤。
J Nanobiotechnology. 2019 Jan 25;17(1):18. doi: 10.1186/s12951-019-0451-9.
10
Rebuilding Postinfarcted Cardiac Functions by Injecting TIIA@PDA Nanoparticle-Cross-linked ROS-Sensitive Hydrogels.通过注射 TIIA@PDA 纳米粒子交联的 ROS 敏感水凝胶来重建心肌梗死后的心脏功能。
ACS Appl Mater Interfaces. 2019 Jan 23;11(3):2880-2890. doi: 10.1021/acsami.8b20158. Epub 2019 Jan 10.